Metabolic Selection via Serine Biosynthesis Pathway Patent Application

The USPTO has published a new patent application, US20260085327A1, related to metabolic selection via the serine biosynthesis pathway. The application details an isolated mammalian cell with reduced expression of Phosphoserine Phosphatase (PSPH) and its use in recombinant protein production.

Base Editing of Plant Cell Organelle DNA

The USPTO has published a patent application (US20260085323A1) detailing a method for base editing plant cell organelle DNA. The application, filed by the Institute for Basic Science, describes a composition and method for editing adenine to guanine and cytosine to thymine in plant cell organelle DNA.

USPTO Patent Application for Fusion Polypeptides

The USPTO has published a new patent application (US20260085300A1) detailing systems and compositions for fusion polypeptides and their methods of use in regulating target genes. The application was filed on October 27, 2023, by inventors Thomas Blair Gainous, Xiao Yang, Giovanni Carosso, Lei S. Qi, and Daniel O. Hart, II.

Polyproline Nanocage Compound and Manufacturing Method

The USPTO has published a patent application for a polyproline nanocage compound and its manufacturing method. The application details a compound comprising two cyclic peptide scaffolds connected by molecules, with each scaffold containing polyproline helix rods and turn-angle molecules. This is a routine publication of a new patent application.

Heterodimeric Human IgG1 Polypeptides with Isoelectric Point Modifications

The USPTO has published a new patent application, US20260085132A1, titled 'Heterodimeric Human IgG1 Polypeptides with Isoelectric Point Modifications'. The application details methods for purifying desired heterodimer immunoglobulin variants from contaminating homodimer variants by modifying isoelectric points.

Patent Application: Bispecific Antibodies and Uses Thereof

The USPTO has published a new patent application (US20260085131A1) for bispecific antibodies and their uses. The application, filed on August 20, 2025, describes antibodies that bind to two different antigens with varying affinities.

Takeda's Monoclonal Antibody Inhibitor of Factor XIIa Patent Application

The USPTO has published a patent application from Takeda Pharmaceutical Company Limited for a monoclonal antibody inhibitor of Factor XIIa. The application, filed on August 12, 2025, describes methods for treating diseases associated with Factor XII, including hereditary angioedema and ocular diseases.

CD163 Binding Protein Patent Application

The USPTO has published a patent application (US20260085129A1) filed by ECO ANIMAL HEALTH LTD. on October 11, 2023. The application relates to an antibody that binds to porcine CD163, specifically its membrane-bound form.

Anti-CD157 Antibodies, Fragments, Compositions, and Methods

The USPTO has published a patent application (US20260085128A1) detailing anti-CD157 antibodies, antigen-binding fragments, compositions, and methods for their use. The application was filed on July 18, 2023, and describes potential diagnostic reagents and kits.

Bispecific Antibody Targets TIM-3 and CD39 for Cancer

The USPTO has published a patent application (US20260085127A1) for a bispecific antibody designed to target both TIM-3 and CD39 antigens. This antibody aims to enhance immune activity against cancer cells and is intended for cancer treatment.